{
    "paper_id": "6bc8a14545739ea72d0a898c770f394259392359",
    "metadata": {
        "title": "Urgent need for evaluating agonists of Angiotensin-(1-7)/ Mas receptor axis for",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "1. Severity of COVID-19 is likely to be due to blockade of ACE2 actions 8 2. It results in higher angiotensin II and lower angiotensin-(1-7) activities 9 3. Angiotensin-(1-7)/MasR axis is implicated in countering effects of angiotensin II. [8, 9] . However, convincing benefits of using these agents are lacking. ",
            "cite_spans": [
                {
                    "start": 240,
                    "end": 243,
                    "text": "[8,",
                    "ref_id": null
                },
                {
                    "start": 244,
                    "end": 246,
                    "text": "9]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "ACE2 is a key regulatory enzyme in the system responsible for degradation of bioactive 60 angiotensin II to angiotensin-(1-7). Angiotensin II has been shown to be the culprit in hypertension, CVD, diabetes, etc. Angiotensin II increases blood pressure through its action 62 on AT1 receptor (AT1R) expressed in renal and cardiovascular system. Activation of the 63 receptors expressed in human lung tissues has been reported to induce pulmonary fibrosis 64 [12] . It was shown to be involved in promoting tissue remodeling through formation of (1-7)/MasR axis by reducing of pro-inflammatory cytokines [40] . were also reported in males with different co-morbidities [46, 47] . Males had been shown to 154 have a higher vascular and renal sensitivity to angiotensin II compared to females possibly 155 explaining their higher frequency of severe SARS-Cov-2 infections in them [48] .",
            "cite_spans": [
                {
                    "start": 456,
                    "end": 460,
                    "text": "[12]",
                    "ref_id": null
                },
                {
                    "start": 601,
                    "end": 605,
                    "text": "[40]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 666,
                    "end": 670,
                    "text": "[46,",
                    "ref_id": null
                },
                {
                    "start": 671,
                    "end": 674,
                    "text": "47]",
                    "ref_id": null
                },
                {
                    "start": 701,
                    "end": 704,
                    "text": "154",
                    "ref_id": null
                },
                {
                    "start": 875,
                    "end": 879,
                    "text": "[48]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "59"
        },
        {
            "text": "Functionality of RAS has been shown to be influenced by gender and sex hormones [49] . ",
            "cite_spans": [
                {
                    "start": 80,
                    "end": 84,
                    "text": "[49]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "156"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe 187 Covid-19",
            "authors": [
                {
                    "first": "Wang",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "188",
            "issn": "2",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The FDA-approved Drug Ivermectin inhibits the 189 replication of SARS-CoV-2 in vitro",
            "authors": [
                {
                    "first": "Druce",
                    "middle": [],
                    "last": "Caly",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Catton",
                    "suffix": ""
                },
                {
                    "first": "Wagstaff",
                    "middle": [],
                    "last": "Jans",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Antiviral Res",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Chloroquine and hydroxychloroquine in covid-19",
            "authors": [
                {
                    "first": "Aronson",
                    "middle": [],
                    "last": "Ferner",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BMJ",
            "volume": "369",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in 192",
            "authors": [
                {
                    "first": "Wang",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Effect of angiotensin-converting enzyme inhibition and 194 angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2",
            "authors": [
                {
                    "first": "Jessup",
                    "middle": [],
                    "last": "Ferrario",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Chappell",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circulation",
            "volume": "195",
            "issn": "",
            "pages": "2605--2615",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Urinary angiotensin-converting enzyme 2 in hypertensive 197 patients may be increased by olmesartan, an angiotensin II receptor blocker",
            "authors": [
                {
                    "first": "Moniwa",
                    "middle": [],
                    "last": "Furuhashi",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mita",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Am J Hypertens",
            "volume": "198",
            "issn": "",
            "pages": "15--21",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Clinical and biochemical indexes from 2019-nCoV infected patients 200 linked to viral loads and lung injury",
            "authors": [
                {
                    "first": "Yang",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Sci China Life Sci",
            "volume": "63",
            "issn": "",
            "pages": "364--374",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Renin-angiotensin system inhibitors improve the clinical outcomes 202 of COVID-19 patients with hypertension",
            "authors": [
                {
                    "first": "Xiao",
                    "middle": [],
                    "last": "Meng",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Emerg Microbes Infect",
            "volume": "9",
            "issn": "",
            "pages": "757--760",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Renin-Angiotensin-Aldosterone System Inhibitors in 204 Patients with Covid-19",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Vaduganathan",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Vardeny",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Michel",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Cardiovascular Implications of Fatal Outcomes of Patients With 206 Coronavirus Disease 2019 (COVID-19)",
            "authors": [
                {
                    "first": "Fan",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA Cardiol",
            "volume": "207",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Are patients with hypertension and diabetes mellitus at increased 208 risk for COVID-19 infection?",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "Roth",
                    "middle": [],
                    "last": "Karakiulakis",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "209",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Distribution of type-1 and type-2 angiotensin receptors in the 210 normal human lung and in lungs from patients with chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Bullock",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Steyaert",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Bilbe",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Histochem Cell Biol",
            "volume": "115",
            "issn": "211",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Angiotensin II-induced production of mitochondrial reactive oxygen 213 species: potential mechanisms and relevance for cardiovascular disease",
            "authors": [
                {
                    "first": "Nazarewicz",
                    "middle": [],
                    "last": "Dikalov",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antioxid Redox 214 Signal",
            "volume": "19",
            "issn": "",
            "pages": "1085--94",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Angiotensin AT1/AT2 receptors: regulation, signalling and function",
            "authors": [
                {
                    "first": "Unger",
                    "middle": [],
                    "last": "Kaschina",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood",
            "volume": "216",
            "issn": "",
            "pages": "70--88",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Vascular relaxation, antihypertensive effect, and 218 cardioprotection of a novel peptide agonist of the MAS receptor",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Savergnini",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Beiman",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Lautner",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Santos: Angiotensin",
            "volume": "219",
            "issn": "1-7",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Simoes: The Anti-Inflammatory Potential of 222",
            "authors": [
                {
                    "first": "Rodrigues",
                    "middle": [],
                    "last": "Prestes",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rocha",
                    "suffix": ""
                },
                {
                    "first": "Teixeira",
                    "middle": [],
                    "last": "Miranda",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Mas Receptor Axis: Evidence from Basic and Clinical Research",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Ace2/Angiotensin",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Curr 223 Drug Targets",
            "volume": "18",
            "issn": "",
            "pages": "1301--1313",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "The Angiotensin-(1-7)/Mas Axis Improves Pancreatic beta-225 Cell Function in Vitro and in Vivo",
            "authors": [
                {
                    "first": "Wolke",
                    "middle": [],
                    "last": "Sahr",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Maczewsky",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Endocrinology",
            "volume": "157",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Angiotensin-(1-7)-angiotensin-converting enzyme 2 227 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Gwathmey",
                    "suffix": ""
                },
                {
                    "first": "Reid",
                    "middle": [],
                    "last": "Pendergrass",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Hypertension",
            "volume": "55",
            "issn": "",
            "pages": "166--71",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Favorable Vascular Actions of Angiotensin-(1-7) in 230 Human Obesity",
            "authors": [
                {
                    "first": "Tesauro",
                    "middle": [],
                    "last": "Schinzari",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Veneziani",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Hypertension",
            "volume": "71",
            "issn": "",
            "pages": "185--191",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "The Vasoactive Mas Receptor in Essential 232 Hypertension",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Povlsen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Grimm",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wehland",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Infanger",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kruger",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Med",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "234 administered before and after chemotherapy in patients with newly diagnosed breast 235 cancer",
            "authors": [
                {
                    "first": "Oliver",
                    "middle": [],
                    "last": "Rodgers",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "diZerega: Phase I/II dose escalation study of angiotensin",
            "volume": "57",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel 240 Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Acute respiratory distress syndrome leads to 242 reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin 243 II receptor antagonist",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Wosten-Van Asperen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Lutter",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Specht",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Pathol",
            "volume": "225",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Age-Associated Changes in the Vascular Renin-Angiotensin System in 245 Mice",
            "authors": [
                {
                    "first": "Kim",
                    "middle": [],
                    "last": "Yoon",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Oxid Med Cell Longev",
            "volume": "246",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Intensive care management of coronavirus disease 2019 (COVID-19): 247 challenges and recommendations",
            "authors": [
                {
                    "first": "Weng",
                    "middle": [],
                    "last": "Phua",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Ling",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "248",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Histopathologic Changes and SARS-CoV-2 Immunostaining in the 249 Lung of a Patient With COVID-19",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ann Intern Med",
            "volume": "250",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Why do patients with interstitial lung diseases fail in the ICU? a 251 2-center cohort study",
            "authors": [
                {
                    "first": "Tatar",
                    "middle": [],
                    "last": "Gungor",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Salturk",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Respir Care",
            "volume": "58",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Clinical predictors of mortality due to COVID-19 based on an 253 analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020",
            "authors": [
                {
                    "first": "Yang",
                    "middle": [],
                    "last": "Ruan",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Song",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "254",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and 255 Death in Patients With Coronavirus Disease",
            "authors": [
                {
                    "first": "Chen",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Intern",
            "volume": "256",
            "issn": "2020",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Angiotensin II induces neutrophil accumulation in vivo through 258 generation and release of CXC chemokines",
            "authors": [
                {
                    "first": "Mateo",
                    "middle": [],
                    "last": "Nabah",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Estelles",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Circulation",
            "volume": "110",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Angiotensin II-mediated 260 microvascular thrombosis",
            "authors": [
                {
                    "first": "Russell",
                    "middle": [],
                    "last": "Senchenkova",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Almeida-Paula",
                    "suffix": ""
                },
                {
                    "first": "Granger",
                    "middle": [],
                    "last": "Harding",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Hypertension",
            "volume": "56",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis 262 protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived 263 ROS-mediated RhoA/Rho kinase pathway",
            "authors": [
                {
                    "first": "Li",
                    "middle": [],
                    "last": "Meng",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Antioxid Redox Signal",
            "volume": "22",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Angiotensin-(1-7) Promotes Resolution of Neutrophilic 265 Inflammation in a Model of Antigen-Induced Arthritis in Mice",
            "authors": [
                {
                    "first": "Magalhaes",
                    "middle": [],
                    "last": "Barroso",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Galvao",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Front Immunol",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "The angiotensin-converting enzyme 2/angiotensin-267 (1-7)/Mas receptor axis: a potential target for treating thrombotic diseases",
            "authors": [
                {
                    "first": "Da",
                    "middle": [],
                    "last": "Fraga-Silva",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Silva",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Montecucco",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Thromb 268 Haemost",
            "volume": "108",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "New insights into the elucidation of 270 angiotensin-(1-7) in vivo antiarrhythmic effects and its related cellular mechanisms",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Joviano-Santos",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Santos-Miranda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Joca",
                    "suffix": ""
                },
                {
                    "first": "Ferreira",
                    "middle": [],
                    "last": "Cruz",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Exp 271 Physiol",
            "volume": "101",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Anti-inflammatory effects of the activation of the 275 angiotensin-(1-7) receptor, MAS, in experimental models of arthritis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Da Silveira",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Coelho",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Vieira",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Immunol",
            "volume": "276",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Therapeutic implications of the vasoprotective axis of the 278 renin-angiotensin system in cardiovascular diseases",
            "authors": [
                {
                    "first": "Santos",
                    "middle": [],
                    "last": "Ferreira",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Bradford",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Hypertension",
            "volume": "55",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "A pilot clinical trial of recombinant human angiotensin-converting 280 enzyme 2 in acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Khan",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Benthin",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zeno",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Crit Care",
            "volume": "21",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Vanessa Monteil Inhibition of SARS-CoV-2 infections in engineered human tissues using 282 clinical-grade soluble human ACE2",
            "authors": [],
            "year": 2020,
            "venue": "Cell",
            "volume": "283",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Age-dependent differences in pulmonary host responses 284 in ARDS: a prospective observational cohort study",
            "authors": [
                {
                    "first": "Van",
                    "middle": [],
                    "last": "Schouten",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kaam",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kohse",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Ann Intensive Care",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Angiotensin converting enzyme 2/Ang-(1-7)/mas axis protects brain 286 from ischemic injury with a tendency of age-dependence",
            "authors": [
                {
                    "first": "Li",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "CNS Neurosci Ther",
            "volume": "20",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Circulating angiotensin-converting enzyme 2 activity in 288 patients with chronic kidney disease without previous history of cardiovascular disease",
            "authors": [
                {
                    "first": "Riera",
                    "middle": [],
                    "last": "Anguiano",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Pascual",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Circulating ACE2 activity is increased in patients 291 with type 1 diabetes and vascular complications",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soro-Paavonen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gordin",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Forsblom",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Hypertens",
            "volume": "30",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Gender differences in response to acute and chronic 293 angiotensin II infusion: a translational approach",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Toering",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Van Der Graaf",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Visser",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Physiol Rep",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Sex differences in the metabolic effects of the renin-angiotensin 295 system",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                },
                {
                    "first": "Arnold",
                    "middle": [],
                    "last": "Fleeman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Biol Sex Differ",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "MasR agonists have shown organ-protective effects in preclinical studies. 11 5. The agonists need to be evaluated for COVID-19 treatment for decreasing mortality 12 Abstract: 13 ACE2 being a receptor of entry of SARS-CoV-2 into the host cells, its upregulation has been 14 implicated in increasing susceptibility of individuals to the infections. Clinical picture of 15 COVID-19 suggests a role ACE2 blockade, rather than its overexpression, in causing the 16 pathogenesis. ACE2 blockade results in increased Angiotensin II activity with simultaneous 17 hampering of functions of Angiotensin-(1-7)/MasR axis. Acute respiratory distress due to 18 interstitial pulmonary fibrosis, cardiomyopathy and shock reported in COVID-19 patients can 19 be explained by imbalanced Angiotensin II and Angiotensin-(1-7) activities. Failure of 20 Angiotensin II type 1 receptor blockers to control severity of SARS-CoV-2 infections 21 indicates importance of simultaneous induction of Angiotensin-(1-7)/MasR axis for 22 correcting pathological conditions in COVID-19 through its anti-fibrotic, anti-inflammatory, 23 vasodilatory and cardioprotective roles. MasR agonists have also shown organ protective 24 effects in a number of animal studies. Unfortunately, these agonists have not been tested in 25 clinical studies. Their urgent evaluation in seriously ill COVID-19 patients is urgently 26 warranted to reduce mortality due to the infections. 27 New Modalities for managing serious patients with COVID-19 are utmost important 28 considering increasing spread and number of deaths due to the SARS-CoV-2 infections",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Angiotensin-converting enzyme 2 (ACE2) and COVID-19 36 ACE2 acts as a receptor for SARS-CoV-2 entry into the cells by interacting with S protein of 37 the virus. Interaction between ACE2 and S protein has been shown to be responsible for38 infectivity as well as severity of the infection. Individuals with hypertension, cardiovascular 39 diseases (CVD) or diabetes showing higher expression of ACE2 have been shown to be at a 40 higher risk of developing serious infections with SARS-CoV-2 [4]. ACE2 upregulation has 41 also been shown to occur upon administration of ACE inhibitors (ACE-I) / angiotensin II 42 type-I receptor blockers (ARBs) which are commonly used for managing these conditions [5, 43 6] predisposing them to a higher risk of infections with SARS-CoV-2. Individuals with 44 COVID-19 have been also shown to have higher ACE2 levels correlating with viral load [7] 45 suggesting its role in COVID-19 pathogenesis. This is in contrast with the earlier reports 46 about ACE2 which have shown its role in reducing inflammation. Based on the controversial 47 opinions about continuing the medications up-regulating ACE2 levels, guidelines do 48 recommend their continuation because of lack of evidence of benefit after their 49 discontinuation. Contrarily, few reports have highlighted potential benefits of these drugs in 50 COVID-19 patients",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "51Mortality was reported in 36.8% patients on ACE inhibitors/ARBs versus in 25.6%52 individuals without their use in one of the reports on COVID-19 [10]. Role of ACE2 53 polymorphisms in increasing the risk of SARS-CoV-2 infection has been suggested among 54 Asian population [11]. However, role of the polymorphism is questionable considering 55 increasing numbers of deaths even in western countries. Further investigations for 56 understanding interactions between SARS-CoV-2 and Renin Angiotensin system (RAS) are 57 required for devising effective management strategies.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "65reactive oxygen species (ROS)[13]. Angiotensin II type 2 receptors (AT2R), in contrast to 66 AT1R, exert vasodilatory effects. However they show lower tissue expression in adults[14]    67 indicating their limited role in countering effects of AT1R.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "MasR) to oppose deleterious effects elicited by Angiotensin II [15]. It has been 72 shown to exert anti-hypertensive, cardioprotective actions through vasodilatory and 73 antiarrhythmic effects [16]. It also showed anti-inflammatory and anti-fibrotic effects and has 74 been shown to inhibit pro-inflammatory cytokines like TNF-\u03b1 and IL-6 [17]. Moreover, it 75increased insulin secretion through improvement of pancreatic \u03b2-cell function in mice[18]. It 76 also downregulated reactive oxygen species protecting different cells from injury[19].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "was reported to counteract the hemodynamic abnormalities in a clinical 78 study undertaken in obese individuals [20]. Different MasR agonist like AVE 0991, 79 hydroxypropyl \u03b2-cyclodextrin (HP\u03b2CD)/Angiotensin-(1-7), cyclic angiotensin-(1-7), CGEN-80 856 and CGEN-857 had been shown to exert protective effect when tested preclinically [21].81The agonists were reported to possess antihypertensive and cardioprotective activities with 82 higher in-vivo stability than that of Angiotensin-(1-7) in animal studies[15]. Clinical trials 83 for evaluating Angiotensin-(1-7) have shown it to be safe, well tolerated and devoid any84 dose-limiting toxicities [22]. TXA127, a pharmacological formulation of Angiotensin-(1-7), 85 has been granted orphan drug status by FDA for the treatment of a number of conditions like 86 pulmonary arterial hypertension, Duchenne muscular dystrophy, etc. [23]. Unfortunately, 87 clinical studies for generating safety data on the other agonists are lacking.88 Possible role of imbalanced effects of angiotensin II and Angiotensin-(1-7)/MasR in 89 mediating pathogenesis of COVID-19: 90 Course of COVID-19 has been divided in 3 clinical stages namely asymptomatic, upper 91 respiratory tract involvement and progression to ARDS [24]. Around 20% patients with 92 COVID-19 progress to stage 3 with a mortality rate of around 3-4%. Serious infections mainly occur in elderly patients with underlying comorbidities [these patients are available. However, low angiotensin-(1-7) levels have been 99 observed in ARDS in animal studies in bronchoalveolar lavage fluid [26]. Hence studies are 100 required to assess levels of angiotensin-(1-7) in COVID-19 to understand its role in the 101 pathology. Old age had been shown to be associated with increased expressions of 102 Angiotensin II and AT1R and decreased expression of MasR [27]. This might explain 103 accentuation of pathologies in old age leading to severe infections. Blockade of Angiotensin 104 II activity through AT1R by ARBs has not shown much protection against the severity of 105 infection indicating limited protection offered through activation of AT2R by Angiotensin II. 106 It also stresses the importance of induction of angiotensin-(1-7)/MasR axis for controlling the 107 disease severity. 108 The severe infections have been associated with acute respiratory distress syndrome (ARDS), 109 cardiomyopathy, shock and renal dysfunction [25, 28]. Patients with COVID-19 present with 110 pneumonia and show loose interstitial fibrosis in lung tissue on histopathological examination 111 [29]. High mortality rate has been reported in patients of acute respiratory failure with 112 interstitial lung diseases requiring mechanical ventilators [30]. Around 97% of patients with 113 COVID-19 requiring mechanical ventilator were reported to die in a study conducted in 114 Wuhan [31] indicating need for using anti-fibrotic agents for controlling pulmonary fibrosis 115 in these patients. ARDS in COVID-19 has also been shown to be associated with neutrophilia 116 and coagulation dysfunctions [32]. In addition to contributing to fibrosis, Angiotensin II has 117 been shown to induce neutrophil accumulation [33] and microvascular thrombosis [34]. 118 Contrarily, angiotensin-(1-7)/MasR axis has been shown to inhibit pulmonary fibrosis [35], 119 induce apoptosis of neutrophils [36] and protect from thrombosis [37]. Myocardial injury has 120also been shown to be significantly associated with fatal outcome of Inflammation is thought to be a potential mechanism for myocardial injury causing cardiacdysfunction and arrhythmias [10]. Protective effects of angiotensin-(1-7) on cardiac 123 arrhythmias have been demonstrated in '\u00efn vivo' experiments in rats [38]. Inflammation and 124 cytokine storm which have been shown to contribute shock in COVID-19 patients [39] 125 indicate possible protection of the patients through anti-inflammatory effect of angiotensin-126",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "protection through activation of Angiotensin-(1-7)/MasR axis 129 Beneficial effects of Angiotensin-(1-7)/MasR axis demonstrate its therapeutic potential to 130 counter pathologies reported in patients with COVID-19. Patients with mild disease confined 131 mainly to upper respiratory tract just require conservative symptomatic therapy. However, 132 patients in stage 3 disease presenting with hypoxia and pulmonary infiltrates need a rigorous 133 management and need to be evaluated for treatment with Angiotensin-(1-7)/MasR axis 134 agonists for reducing mortality. Interestingly, ACE2 and MasR have been shown to be 135 expressed in the same tissues [41], indicating protective role of MasR agonists in controlling 136 effects of ACE2 blockade in organs affected in COVID-19. Agonists of Angiotensin-(1-137 7)/MasR axis have been reported to exert Angiotensin-(1\u22127) mimicking effects in different 138 organs like blood vessels, brain, kidney and neuronal tissues [21]. Such organ specific effect 139 is likely to be lacking if soluble ACE2 is used for treatment of COVID-19. Treatment with 140 soluble ACE2 had been shown to reduce Angiotensin II levels and increase angiotensin-(1-7) 141 levels in a clinical trial on patients with ARDS [42]. However, these effects are likely to 142 occur at systemic levels as evident from lack of the clinical benefits reported in the trial [42]. 143 Hence soluble ACE2, although might block SARS-CoV-2 infections in early stages as shown 144 in a recent publication on the same [43], would have limited efficacy in severely ill COVID-145 19 patients as it would lack organ specific effects.146 Possible effect of age and gender on ACE2-Angiotensin-(1-7)/MasR axis 147 Interestingly, older animal studies have shown lower ACE2 expressions [27] contradicting 148 the findings of higher susceptibility of elderly individuals to severe infections. However, no 149 age dependent changes in ACE2 levels were observed in a study done in human beings [44]. were also found to have lower expression of MasR. However, AVE 0991 had 151 been shown to exert greater protective effect in older animals [45]indicating possible 152 effectiveness of the agonists in old aged individuals with COVID-19. Higher ACE2 levels 153",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Angiotensin-(1-7) levels have also been shown to vary with gender of animals, 158 protective effects of AVE 0991 have been demonstrated in both male and female animals 159[40].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "ACE2 expression has been implicated in increasing susceptibility of 163 individuals to SARS-CoV-2 infections, severity of the infections is likely to be caused by 164 blockade of ACE2 actions rather than its overexpression if the clinical picture of COVID-19 165 is considered. ACE2 blockade is likely to lead to excessive levels of Angiotensin II along 166 with deficiency of Angiotensin-(1-7)/MasR axis. Failure of ARBs to control severity of 167 SARS-CoV-2 infections suggests need for simultaneous induction of Angiotensin-(1-7)/ 168 MasR axis for controlling the disease severity. Mechanism of action of Angiotensin-(1-7) 169 /MasR axis indicates its potential for countering organ specific adverse events occurring due 170 to ACE2 blockade in COVID-19 patients. In spite of multiple reports on beneficial effects of 171 oral and injectable MasR agonists in animal models, they have not been tested clinically. The 172 crisis condition of the SARS-CoV-2 infections and ever-increasing number of deaths caused 173 by it warrant their urgent evaluation in seriously ill COVID-19 patients. of interest to declare.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "world-wide. Unfortunately lopinavir-ritonavir treatment failed to demonstrate significant clinical improvement and reduce mortality in patients with serious COVID-19 infections [1].Although drugs like Hydroxychloroquine, Azithromycin and Ivermectin have been proposed to improve viral clearance [2, 3], sufficient evidence for their efficacy in COVID-19 patients is warranted. Lack of effective treatment modalities for managing severe illness has caused a large number of deaths even in developed countries with the topmost health care facilities.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}